This morning the CSL Limited (ASX: CSL) share price edged higher once again and reached a 52-week high of $142.75.
This means the biotherapeutics company's shares have now gained over 41% since the turn of the year.
Why did its shares jump today?
This morning CSL announced that the U.S. Food and Drug Administration has approved its HAEGARDA subcutaneous therapy.
The therapy, indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients, is a self-administered, plasma-derived concentrate of the C1 esterase inhibitor injected twice weekly subcutaneously.
According to the release, HAE is a rare, genetic, and potentially life-threatening condition that causes painful, debilitating, and unpredictable episodes of swelling on the body.
The approval by the FDA means that HAEGARDA is the first and only subcutaneous preventive treatment option on the market.
Earlier this year CSL reported a 36% increase in underlying half-year net profit after tax to $806 million.
